Impact of Investigational Dose of Semaglutide Injection on Treatment Options for Patients With Type 2 Diabetes

Pharmacy Times interviewed Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, on results from the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide (Ozempic; Novo Nordisk) injection in adults with type 2 diabetes.

During the discussion, Radin addresses why the results of the SUSTAIN FORTE trial are important to the field, and how the trial findings could change treatment options for patients with type 2 diabetes.